This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Iwaki, Y. Articles by Morton, D. L. Search for Related Content PubMed PubMed Citation Articles by Iwaki, Y. Articles by Morton, D. L.

Monoclonal Antibody against A₁ Lewis d Antigen Produced by the Hybridoma Immunized with a Pulmonary Carcinoma¹

Departments of Surgery [Y. I., P. I. T., D. B., M. S. P., J. C., R. H.] and Surgical Oncology [M. K., R. E. S., M. W. B., D. L. M.], UCLA School of Medicine, University of California, Los Angeles, California 90024

A monoclonal antibody (CALed) against a human pulmonary squamous cell carcinoma line was cytotoxic to the line but did not react to an autologous B-lymphoblastoid line. Although the antibody was thought to be cancer specific, principally on the basis of this evidence, the antibody actually had the A₁ Lewis d (Le^d) specificity. It reacted with approximately 2% of the random donor T-lymphocytes and with all six lymphocytes from donors who were A₁ Le^d type without reacting to lymphocytes of any other type. The monoclonal antibody reactivity was also absorbed out by A₁ Le^d red blood cells but not by red cells of other types. We conclude that the A₁ Le^d antigen had been synthesized by the pulmonary carcinoma lines but not by the autologous lymphoblastoid line, resulting in disparity for this antigen. Since the combination A₁ Le^d only occurs in 2% of the population, it is difficult to distinguish this type of antibody from tumor-specific antibodies.

¹ Supported in part by Grant AM 2375 from NIH and USPHS AI 15332.

² To whom requests for reprints should be addressed.

Received 5/ 7/81. Accepted 11/ 2/81.